Fosun Pharma: A new subsidiary of the holding subsidiary completed the clinical phase I trial
Fosun Pharma announced that the recombinant anti-VEGF humanized monoclonal antibody injection developed by Fuhong Hanlin, a controlled subsidiary of the company, completed the clinical phase I trial and recently launched the new drug for the treatment of metastatic colorectal cancer indications. Phase III trial. The new drug is a monoclonal antibody biosimilar drug independently developed by the company. It is mainly used for the treatment of indications for metastatic colorectal cancer, indications for non-small cell lung cancer, wet age-related macular degeneration and diabetic retinopathy.
Hejing Technology: Introducing the battlefield Jingzhou Huihe tomorrow to resume trading
Hejing Technology announced that the company's controlling shareholder, real controller Chen Bolin and some shareholders plan to introduce new partners in line with the development strategy of listed companies: 6 people including Chen Bolin intend to put 12% of the company's shares, or 53.87 million shares, It was transferred to Jingzhou Huihe Equity Investment Partnership (limited partnership) at 12.2 yuan/share, with a total transfer price of 657 million yuan. After the transaction, the controlling shareholder and actual controller of the company will remain unchanged, and Jingzhou Huihe will become the second largest shareholder of the company. The company's stock resumed trading on the 16th.
Broad Intelligence: Received an invitation letter for overseas PPP project cooperation
Yuanda Intelligent Announcement, the company received the “Power Building Project Cooperation Invitation Letter” issued by the ARSEL organization of the Republic of Cameroon. According to the company's plan and quotation for the construction of the power building project in PPP mode, the company was invited to dispatch a competent operation team to Yawen. Work on the project site and meet to complete the program. The company's offer for the entire power building project is $160 million and the project's operating cycle is 22 years.
Longji shares: plans to build 1.2 million yuan to build Chuxiong single crystal silicon wafer project
Longji announced that in December 2016, the company signed an investment agreement with the Yunnan Chuxiong Yi Autonomous Prefecture Government to reach an agreement on the company's investment in the construction of an annual output of 10 GW of monocrystalline silicon wafers (Phase I project). The project has been partially put into operation. According to the strategic development needs, the company signed a project investment agreement with the relevant parties on April 15, 2018, and added a 10 GW annual monocrystalline silicon wafer project (the second phase project) to the cooperation on the first phase of the project. The investment is expected to be 1.2 billion yuan.
Qingsong shares: 2017 net profit increased by 189%
Qingsong shares (300132) disclosed the annual report on the evening of April 15. The company achieved operating income of 811 million yuan in 2017, a year-on-year increase of 45.56%; net profit of 94.746 million yuan, an increase of 189.44%; earnings per share of 0.25 yuan. The company plans to distribute a bonus of 0.5 yuan for every 10 shares.
Ren Zixing: Pushing 8.96 million restricted stock incentive plans
Ren Zixing (300311) announced the draft of the 2018 Restricted Stock Incentive Plan on the evening of April 15, and proposed to grant 8.96 million restricted stocks, accounting for 2% of the company's total share capital at the time of publication. Among them, 8.14 million shares were granted for the first time, and 820,000 shares were reserved. The total number of incentives granted for the first time was 256, including some directors, senior executives and middle management personnel, core business (technical) personnel, etc.; the price was 6.91 yuan/share; the performance evaluation condition was 2018. 150 million yuan, the net profit in 2019 is not less than 160 million yuan.
Harbin Pharmaceutical Co., Ltd.'s net profit increased more than double in the first quarter
Harbin Pharmaceutical disclosed a quarterly report. The company's operating income for January-March 2018 was 2,857,831,646.74 yuan, down -7.38% year-on-year; net profit attributable to shareholders of listed companies was 140,227,002.06 yuan, up 201.22% year-on-year; basic earnings per share was 0.06 yuan.
Shuo Bad: The net profit in the first quarter increased by more than 4 times
Shuo Baide (300322) disclosed a quarterly report on the evening of April 15. The company achieved a total operating income of 361 million yuan in the first quarter of this year, a year-on-year increase of 14.79%; net profit of 15.5225 million yuan, an increase of 412.62%. In addition, the company's wholly-owned subsidiary, Shuo Baide Hong Kong, will jointly invest in the establishment of a company, Speedlink Technology Inc, with Chen Dongxu and others. Sobide Hong Kong will hold a 55% stake in the company for US$1.65 million. This investment is conducive to grasping the trend of the electronics industry and opening up the North American market.
*ST New City: 2017 net profit exceeded 100 million yuan continued to profit in the first quarter
*ST Xincheng (000809) disclosed the annual report and the first quarterly report on the evening of April 15. The company realized revenue of 797.237 million yuan in 2017, a year-on-year increase of 279.12%; net profit of 101 million yuan, a year-on-year loss, net profit loss of 240 million yuan in the previous year; The income is 0.12 yuan. The net profit loss was mainly due to the realization of land transfer income during the reporting period, and the recovery of the previous year's accounts receivable was reversed to the corresponding provision for bad debts. In the first quarter of this year, the company's profit was 2,090.7 million yuan. The company recovered the accounts receivable and offset the corresponding bad debts, resulting in an increase in cash flow and an increase in profits.
Pien Tze's 2017 net profit increased by more than 50%
Zhang Tsai disclosed the annual report. The company's operating income in 2017 was 3,713,953,975.95 yuan, a year-on-year increase of 60.85%; the net profit attributable to shareholders of listed companies was 807,018,675.04 yuan, an increase of 50.53%; basic earnings per share was 1.34 yuan. Based on the total share capital of 603,317,210 shares of the Japanese company on December 31, 2017, the company distributed cash dividends of 4.30 yuan (including tax) for every 10 shares.
Black sesame: sales of black and black light fat drinks are gradually increasing
Black Sesame (000716) today said on the interactive platform that the company's sales of black and light light fat drinks have gradually increased. The main sales areas are in key markets such as Guangdong, Fujian, Sichuan, Yunnan, Jiangsu, Anhui and other South China, Southwest and East China.
Five taboos: one bogey, two taboos, three taboos, four taboos, and five taboos;
Five conditions: knowledge, patience, courage, health and capital
Crystal ball this week
Huarong (famous senior professional trader): Northeast Pharmaceuticals - a large increase in performance; Weixing shares - valuation is not high, the trend is steady.
Old Chinese (famous investor): Zhongcheng shares - one belt and one road; Honghui fruit and vegetables - agriculture.
Yan Hua (Chairman of Investment Company): Minda Co., Ltd. - Hainan Plate; Shuangcheng Pharmaceutical - Hainan Lake.
Wu Guoping (famous private placement): Light Media - Quality Blue Chips; Anyuan Coal Industry - Growth Shares
Dr. Deng's daily limit warfare (the chairman of the private equity fund company): Tianguang Zhongmao - agriculture; research new materials - chips.
Liu Xinxin (CEO of Capital Management Company): Shennong Gene - Free Trade Zone Concept; Yintai Resources - Gold Concept.
Zhanfeng (investment celebrity): Keda Guochuang - mid-line potential cattle stocks; Jianyi Group - change hands of cattle stocks early warning.
Yuhui Battleship (Financial Economics Bo): Zhong Haida -...